Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) is scheduled to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. The business had revenue of $23.49 million for the quarter, compared to the consensus estimate of $17.24 million. During the same quarter in the previous year, the company earned ($0.27) earnings per share. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Nektar Therapeutics Stock Performance
Nektar Therapeutics stock traded up $0.04 during midday trading on Friday, hitting $1.23. 841,949 shares of the company's stock were exchanged, compared to its average volume of 1,730,080. Nektar Therapeutics has a 12 month low of $0.41 and a 12 month high of $1.93. The firm has a 50-day moving average of $1.28 and a two-hundred day moving average of $1.34. The company has a market cap of $226.42 million, a PE ratio of -1.37 and a beta of 0.60.
Analyst Upgrades and Downgrades
Separately, BTIG Research reiterated a "buy" rating and set a $4.00 target price on shares of Nektar Therapeutics in a report on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $2.33.
Read Our Latest Stock Report on NKTR
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
See Also
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
